Table 1: (a) Graft survival relative to pretransplantation variables: personal factors. (b) Graft survival relative to pretransplantation variables: hematological factors. (c) Graft survival relative to pre-transplantation variables: immunologic factors. (d) Graft survival relative to pretransplantation variables: current and past medical disorders.
(a)

No. of
patients
5-year survival %95% CI10-year survival %95% CIP-value
(log rank)

Donor’s sex
 Male 94488.686.4490.7669.9 66.3773.430.012
 Female102385.082.6587.3561.557.9765.03
Donor’s age (years)
 ≤30 77287.785.3590.0568.564.5872.42<0.001
 31–40 62787.985.1690.6469.665.2973.91
 41–50 38983.479.4887.3258.052.1263.88
 ≥50 17985.379.8190.7952.943.3062.50
Recipient’s sex
 Male146687.685.8489.4664.754.974.500.829
 Female 50184.380.9787.6367.863.1072.50
Recipient’s age (years)
 ≤20 37884.480.6888.1259.052.9265.080.002
 21–3070988.686.2590.9566.962.7871.02
 31–4055686.583.5689.4467.062.4971.51
 41–5027085.781.3990.0167.460.5474.26
 ≥50 5486.775.5397.8771.252.7889.62
The sex donor-recipient
 Male-male 69389.587.1591.8568.2 63.89 72.510.082
 Male-female 25186.181.5990.6174.4 68.1380.67
 Female-male 77385.983.3588.4561.557.38 65.62
 Female-female 25082.677.7087.5061.354.24 68.36
Donor relationship
 Related162087.385.5489.0665.762.9668.440.651
 Unrelated 34784.380.1888.4264.658.3370.87

(b)   

No. of
patients
5-year survival %95% CI10-year survival %95% CIP value
(log rank)

ABO compatibility
 Identical157987.385.5489.0665.863.0668.540.500
 Different compatible 38884.580.78 88.2264.458.7270.08
Type of blood transfusion
 No transfusion104989.187.1489.8069.065.2872.72<0.001
 Third party 90684.281.65 83.0362.859.4766.13
 Donor specific 12
No. of blood transfusion
 No transfusion104989.187.1489.8068.865.08 72.520.001
 1-2 times 30187.183.18 91.0667.361.42 73.18
 3-4 26582.177.40 86.8064.458.1370.67
 ≥5 35283.379.18 87.4257.852.3163.29

(c)

No. of
patients
5-year survival %95% CI
10-year survival %95% CI
P value
(log rank)

HLA-A, B (class I)
 0-MM 15393.289.0897.3271.462.3880.42<0.001
 1-MM 22992.689.0796.1374.167.4480.76
 2-MM 99686.284.0488.3662.759.1766.23
 3-MM 30982.577.9987.0162.456.1368.67
 4-MM 13285.779.4391.9771.062.1879.82
HLA-DR (class II)
 0-MM 20191.587.5895.4277.669.5685.640.010
 1-MM172086.784.9488.4664.561.76 67.24
 2-MM 2
HLA (class I + II) MM
 0-MM 8894.189.099.2079.667.8491.360.001
 1-MM 10293.889.0998.5068.057.0278.98
 2-MM 23490.086.0893.9271.364.6477.96
 3-MM 96886.283.8588.5562.859.0866.52
 4-MM 29082.477.8986.9162.055.5368.47
 5-MM 13185.679.3391.8769.360.2878.32
HLA-A, B, DR (class I and II) MM
 0/1/2 42491.889.0694.5472.167.0077.200.011
 3/4/5/6 1389 85.883.4487.3663.460.4666.34
Genetic considerations
 HLA-ID sibling 15294.492.6496.1679.270.1888.220.005
 1-Haplotype MM (R)132287.785.9489.4664.761.5667.84
 2-Haplotype MM (R + UR) 44983.279.4886.9264.058.5169.49

(d)

No. of
patients
5-year survival %95% CI10-year survival %95% CIP value
(log rank)

Bilharziasis
 (i) Negative144287.6 85.8489.3665.962.7669.04 0.796
 (ii) Positive 52584.681.4687.7464.459.8968.91
Original kidney diseases
 (i) Glomerulonephritis 21482.8 73.7488.0963.556.0570.950.020
 (ii) Chronic pyelonephritis 25990.686.8894.3273.367.2279.38
 (iii) Nephrosclerosis 5084.9 74.5195.2955.439.7271.08
 (iv) Obstructive uropathy 5792.2 84.9599.4576.061.5090.50
 (v) Amyloidosis 3393.9 85.67102.1380.464.5296.28
 (vi) Congenital polycystic 5193.4 86.15100.6555.837.5774.03
 (vii) Hypoplasia 17100.0100.00100.0083.161.54104.66
 (viii) Others 12680.9 73.6588.1558.845.6771.93
 (ix) Not determined 1160
Types of glomerulonephritis (GN)
 (i) Mesangiocapillary GN 3581.8 68.6794.9362.742.9082.500.701
 (ii) Membranous GN 2257.8 36.8378.7757.836.8378.77
 (iii) F.S.G.S. 7090.7 83.6497.7666.653.6679.54
 (iv) Mesangioproliferative GN 2373.9 55.8791.9367.853.6679.54
 (v) Crescentic GN 1687.5 71.23103.7746.717.6975.71
 (vi) Hereditary nephritis 4887.0 77.2096.8065.749.8079.60
Pretransplant hypertension
 (i) Normotensive 82687.2 84.8589.5564.660.4868.720.466
 (ii) Hypertensive114186.4 84.2488.5666.162.7769.43
No. of transplants received
 (i) First189186.085.0388.1765.162.5567.650.242
 (ii) Second 7390.082.9497.0677.867.2288.38
 (iii) Third 3